Side-by-side · Research reference

TeriparatidevsTriptorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED10/62 cited

BFDA-ApprovedHUMAN-REVIEWED16/64 cited

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

Triptorelin

GnRH Agonist · FDA-Approved

3.75–22.5 mgDepot dose rangeYee 2025 Chen 2024

<50 ng/dLTestosterone target

1–6 monthsDepot durationYee 2025 Chen 2024

IM · Depot Injection · Monthly to 6-MonthlyYee 2025

01Mechanism of Action

Parameter

Teriparatide

Triptorelin

Primary target

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pituitary GnRH receptorsUnknown 2012

Pathway

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression

Downstream effect

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare

Feedback intact?

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression

Origin

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability

Antibody development

—

02Dosage Protocols

Parameter

Teriparatide

Triptorelin

Standard dose (osteoporosis)

20 mcg / day

FDA-approved regimen for severe osteoporosis.

—

Frequency

Once daily

Intermittent administration preserves anabolic effect.

Every 1, 3, or 6 months per formulation

Maximum duration

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

—

Hypoparathyroidism dose

20 mcg / day

Used off-label for chronic hypoparathyroidism.

—

Evidence basis

RCT / FDA-approved

Multiple Phase 3 RCTs · FDA-approved 1999

Pelvic fragility fractures

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

—

Route

Subcutaneous (thigh or abdomen)

—

Timing

Morning or evening (flexible)

—

Storage

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

—

Pharmacogenetics

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

—

1-month depot

—

3.75 mg IM

Most common formulation for prostate cancer.

3-month depot

—

11.25 mg IMYee 2025

Reduced injection frequency.

6-month depot

—

22.5 mg IMYee 2025 Chen 2024

Long-acting formulation; improved adherence in real-world use.Yee 2025

Administration route

—

Intramuscular (IM) — gluteal or deltoid

Indication: Prostate cancer

—

Advanced (metastatic or locally advanced)

Androgen deprivation therapy (ADT) backbone.

Indication: Endometriosis

—

3.75 mg monthly

FDA-approved; typically 6-month course.

Indication: Central precocious puberty

—

Pediatric use (≥2 years)Jia 2025

Weight-based dosing per FDA label.

Duration (prostate cancer)

—

Continuous or intermittent ADT protocolsPreston 2024

Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.

Monitoring

—

Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose

03Metabolic / Fat Loss Evidence

Parameter

Teriparatide

Triptorelin

Fat loss application

None — teriparatide is a bone anabolic agent without direct lipolytic activity

—

04Side Effects & Safety

Parameter

Teriparatide

Triptorelin

Hypercalcemia

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

—

Orthostatic hypotension

Dizziness, lightheadedness within hours of injection

—

Nausea

Common, usually mild and transient

—

Leg cramps / Arthralgia

Musculoskeletal pain reported in clinical trials

—

Hypercalciuria

Increased urinary calcium excretion; monitor for nephrolithiasis risk

—

Osteosarcoma (black box warning)

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

—

Injection site reaction

Erythema, bruising, pain (uncommon)

—

Initial flare symptoms

—

Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)

Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.

Cardiovascular events

—

MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025 Preston 2024

Hot flashes

—

Very common (>60%); vasomotor instability

Bone loss / Osteoporosis

—

Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025

Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.

Metabolic syndrome

—

Weight gain, insulin resistance, dyslipidemia, diabetes risk

Sexual dysfunction

—

Erectile dysfunction, loss of libido (expected pharmacological effect)Jia 2025

Injection site reactions

—

Pain, erythema, sterile abscess (rare with depot formulations)

Gynecomastia / Breast tenderness

—

Common (10–20%); peripheral aromatization of residual androgens

Fatigue / Mood changes

—

Anemia, depression, cognitive changes reported in long-term ADT

Hepatotoxicity

—

Transient transaminase elevations; clinically apparent liver injury rare

Racial differences (ADT)

—

Black veterans show higher CV event rates vs White veterans on GnRH agonists

Absolute Contraindications

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Triptorelin

·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
·Pregnancy (Category X)

Relative Contraindications

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

Triptorelin

·Active cardiovascular disease — consider GnRH antagonist alternative
·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
·Severe urinary obstruction — may worsen during flare
·Osteoporosis or high fracture risk (requires bone-protective therapy)

05Administration Protocol

Parameter

Teriparatide

Triptorelin

1. Device preparation

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.

2. Injection site

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.

3. Timing

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.

4. Injection technique

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.

5. Monitoring

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.

6. Calcium and vitamin D supplementation

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.

Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.